Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-PACE: Phase 2 study of Imgatuzumab in advanced cutaneous squamous cell carcinoma
2021-003262-12Phase 2Completed
- Sponsor
- PegaOne
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imgatuzumab in cutaneous squamous cell carcinoma (cSCC), sponsored by PegaOne. Primary endpoint: Overall response rate. Started Feb 2022; status: completed.
02
Drugs
imgatuzumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2021-003262-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003262-12.